Related Experiment Video
Updated: Mar 20, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.4K
Genetics in Anti-Platelet Treatment
1Molecular Biology, Department of Basic Medical Science, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece.
Current Pharmaceutical Design
|June 6, 2016
Summary
Individual response to anti-platelet drugs like aspirin and clopidogrel varies due to genetic factors. Understanding these genetic mechanisms is key to improving treatment for patients with cardiovascular diseases.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Anti-platelet drugs are crucial for managing coronary artery disease, ischemic stroke, and peripheral arterial disease.
- A subset of patients exhibits inadequate response to anti-platelet therapy, leading to recurrent atherothrombotic events.
- Variability in patient response to drugs like clopidogrel and aspirin is a significant clinical challenge.
Purpose of the Study:
- To review the genetic factors influencing individual responsiveness to anti-platelet therapy.
- To elucidate the genetic mechanisms underlying low or non-response to anti-platelet medications.
- To highlight the importance of pharmacogenetics in optimizing anti-platelet treatment strategies.
Main Methods:
- Literature review focusing on genetic polymorphisms and their impact on anti-platelet drug efficacy.
- Analysis of studies investigating genetic variations in drug metabolism and target pathways.
- Synthesis of current knowledge on genetic determinants of anti-platelet response.
Main Results:
- Genetic factors significantly contribute to the wide variability in patient response to anti-platelet agents.
- Specific gene variants are associated with reduced efficacy of clopidogrel and aspirin.
- Environmental factors also play a role, interacting with genetic predispositions.
Conclusions:
- Genetic variability is a primary driver of differential responses to anti-platelet drugs.
- Identifying genetic markers can potentially personalize anti-platelet therapy.
- Further research into pharmacogenetics is essential for improving outcomes in patients at risk of atherothrombotic events.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
98
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
01:22Formation of the Platelet Plug
10.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.5K